JP3754785B2 - Method for producing 3-hydroxy nitrogen-containing six-membered ring compound - Google Patents

Method for producing 3-hydroxy nitrogen-containing six-membered ring compound Download PDF

Info

Publication number
JP3754785B2
JP3754785B2 JP2916097A JP2916097A JP3754785B2 JP 3754785 B2 JP3754785 B2 JP 3754785B2 JP 2916097 A JP2916097 A JP 2916097A JP 2916097 A JP2916097 A JP 2916097A JP 3754785 B2 JP3754785 B2 JP 3754785B2
Authority
JP
Japan
Prior art keywords
rhodococcus
membered ring
strain
ring compound
acid derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2916097A
Other languages
Japanese (ja)
Other versions
JPH09275992A (en
Inventor
剛 阪本
幸恵 高井
玲子 指田
誠 上田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Priority to JP2916097A priority Critical patent/JP3754785B2/en
Publication of JPH09275992A publication Critical patent/JPH09275992A/en
Application granted granted Critical
Publication of JP3754785B2 publication Critical patent/JP3754785B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、微生物の菌体、及び/又は該菌体調製物による3−ヒドロキシ含窒素六員環化合物の製造方法に関するものである。3−ヒドロキシ含窒素六員環化合物は医薬の中間原料として有用な物質である。
【0002】
【従来の技術】
3−ヒドロキシ含窒素六員環化合物を製造する方法はこれまでに多数の報告がなされているが、全て化学合成法によるものである。2−アセチルフランをアンモニア存在下で加熱する方法(ジャーナル オヴ メディシナル ケミストリー(J.Med.Chem.),11,792 (1968))、メラノイヂンを熱分解する方法(アグリカルチュラル アンド バイオロジカル ケミストリー(Agr.Biol.Chem.),40,2051 (1976))、2−アミノメチルフランを低温条件下で光酸化する方法(ケミカル アンド ファーマス−ティカル ビュルティン(Chem.Pharm.Bull.,39,181(1991))等がある。
【0003】
【発明が解決しようとする課題】
従来の化学合成による製造法は原料が高価であったり、塩素系有機溶媒を使用したり、不純物が多く回収精製の工程に問題がある等の点で、工業的な製法として必ずしも満足できる方法ではない。
本発明の課題は、工業的に安価に3−ヒドロキシ含窒素六員環化合物を製造する方法を提供することにある。
【0004】
【課題を解決するための手段】
本発明者らは、上記課題を解決するべく鋭意検討した結果、ニコチン酸から3−ヒドロキシ含窒素六員環化合物を生成しうる微生物を見出し、本発明を完成した。即ち、本発明の要旨は、一般式(I)
【化3】

Figure 0003754785
(式中、R1 及びR2 は、それぞれ独立して水素原子、ハロゲン原子、水酸基、アミノ基、カルボキシル基、シアノ基、オキシム基又は炭素数1〜5のアルキル基を表し、AはCH又は窒素原子を表す。)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体に、該誘導体のカルボキシル基の脱炭酸を伴う水酸化能力を有する微生物の菌体及び/又は該菌体調製物を作用させることを特徴とする、一般式(II)
【化4】
Figure 0003754785
(式中、R1 、R2 及びAは式(I)と同義である。)で表される3−ヒドロキシ含窒素六員環化合物の製造方法にある。
【0005】
本発明は、好ましい実施の形態として、
(1)ニコチン酸に、ニコチン酸のカルボキシル基の脱炭酸を伴う水酸化能力を有する微生物の菌体及び/又は該菌体調製物を作用させることを特徴とする3−ヒドロキシ含窒素六員環化合物の製造方法、ならびに
(2)6−クロロニコチン酸に、6−クロロニコチン酸のカルボキシル基の脱炭酸を伴う水酸化能力を有する微生物の菌体及び/又は該菌体調製物を作用させることを特徴とする3−ヒドロキシ含窒素六員環化合物の製造方法、
を提供する。
尚、上記の微生物としては、ロドコッカス属に属する微生物が好ましいものとして挙げられる。
以下、本発明の方法について詳細に説明する。
【0006】
【発明の実施の形態】
本発明においては、原料として上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体を用い、これに上記特定の微生物の菌体又は該菌体調製物を作用させて、上記一般式(II)で表される3−ヒドロキシ含窒素六員環化合物を製造する。式中、R1 及びR2 が示す炭素数1〜5のアルキル基とは、例えば、メチル基、エチル基、n−プロピル基、iso−プロピル基、n−ブチル基、iso−ブチル基、sec−ブチル基、tert−ブチル基を表す。好ましい例としては、R1 、R2 が水素原子又はハロゲン原子である場合、及びAがCHである場合が挙げられる。特に好ましい例としては、R1 、R2が水素原子を表し、AがCHを表す場合、及びR1がハロゲン原子を表し、R2が水素原子を表し、AがCHを表す場合が挙げられる。
【0007】
本発明においては、上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体のカルボキシル基の脱炭酸を伴う水酸化能力を有する微生物であれば、いずれの微生物も使用し得る。特に好ましい微生物としては、ロドコッカス(Rhodococcus)属あるいはセラチア(Serratia)属に属する微生物が挙げられる。本発明において使用するロドコッカス(Rhodococcus)属あるいはセラチア(Serratia)属に属する微生物は、例えばロドコッカス・ロドクラス(Rhodococcus rhodochrous)ATCC 14350、ロドコッカス・ロドクラス(Rhodococcus rhodochrous)ATCC 19150、ロドコッカス・エクイ(Rhodococcus equi)ATCC 21329、ロドコッカス・エスピー(Rhodococcus sp.)IFO 13161及びロドコッカス・エスピー(Rhodococcus sp.)MCI 2956、セラチア・プリムチカ(Serratia plymuthica)IAM 13543及びセラチア・マルセッセンス(Serratia marcescens)IAM 12142等が挙げられる。上記菌株はロドコッカス・エスピー(Rhodococcus sp.)MCI 2956を除き全て公知の菌株であり、それぞれ工業技術院生命工学工業技術研究所、(財)発酵研究所(IFO)、アメリカンタイプカルチャーコレクション(ATCC)及び東京大学分子生物学研究所(IAM)から容易に入手することができる。ロドコッカス・エスピー(Rhodococcus sp.)MCI 2956は本発明者等により天然土壌から分離された細菌であり、1996年1月29日に工業技術院生命工学工業技術研究所にFERM P−15404として寄託され、1997年2月6日にブダペスト条約に基づく国際寄託に移管され、FERM BP−5813の受託番号で寄託されている。また、上記微生物は、野生株、UV照射、N−メチル−N’−ニトロ−N−ニトロソグアニジン(NTG)処理、エチルメタンスルホネート(EMS)処理、亜硝酸処理、アクリジン処理等による変異株、或いは細胞融合若しくは遺伝子組換え法等の遺伝学的手法により誘導される組換え株等のいずれの株であってもよい。尚、以下に土壌分離菌であるロドコッカス・エスピー(Rhodococcus sp.)MCI 2956の菌学的性状を記す。
【0008】
1.形態的性質
ハートインフュージョン寒天培地上、30℃、培養9時間後及び30時間後に顕微鏡観察を行った。MCI 2956株は培養初期に細胞が不均一に伸張し分枝した菌糸状になる。その後時間の経過と共に細胞は分断(fragmentation)し、短桿状〜不均一な桿状になる。分断した細胞は運動性を有しない。気菌糸、胞子及び胞子嚢は観察されなかった。
【0009】
2.培養的性質
ISP〔インターナショナル・ストレプトマイセス・プロジェクト(International Streptomyces Project)〕規定の培地上、30℃、10日間培養後のMCI 2956株の性状を以下の第1表に示した。
【0010】
【表1】
Figure 0003754785
【0011】
3.生理学的性質
MCI 2956株の生理学的性質を以下に示した。
(1)生育温度範囲 20〜40℃
(2)ゼラチンの液化 陰性
(3)スターチの加水分解 陰性
(4)スキムミルクの凝固、ペプトン化 陰性
(5)メラニン様色素の生成 陰性
(6)炭素源の利用(プリドハム・ゴトリーブ寒天培地上で30℃、14日間培養)
MCI 2956株は炭素源無添加の対照培地でも若干の生育が見られたため、対照を−とした相対的な資化性を第2表に示した。
【0012】
【表2】
Figure 0003754785
【0013】
4.化学分類学的性質
MCI 2956株の化学分類学的性質を第3表に示した。
【0014】
【表3】
Figure 0003754785
【0015】
5.分類学的考察
MCI 2956株はセルサイクル(cell cycle)に多形性を示す。培養初期に細胞は分枝した菌糸状に伸張し、経時的に分断し短桿状〜桿状になる。また、細胞壁にmeso−ジアミノピメリン酸を有し、全菌体糖にアラビノース及びガラクトースを含むことから細胞壁タイプはIV型であることが判明した。更に細胞壁ペプチドグリカンのN−アシル型はグリコリル型であった。これらの特徴から本菌株はノカルディア科(Nocardiaceae)或いはミコバクテリウム(Mycobacterium)属に属することが示唆された。これらの菌群は細胞壁にミコール酸(α位に長鎖アルキル基を有するβ−ハイドロキシ脂肪酸)を持つことが大きな特徴として知られており、その他の化学分類学的特徴によって属の定義が明確に行われている。
【0016】
そこで本菌株とプロオカリオート〔The Prokaryotes〕第2判(1992)、第2巻、1180〜1270頁に記載されているノカルディア科及びミコバクテリウム属の化学分類学的特徴を比較し属レベルの同定を行った。本菌株とノカルディア科に属する菌群及びミコバクテリウム属の形態及び化学分類学的特徴を比較し、第4表に示した。本菌株は培養初期に細胞が伸張し分枝した菌糸状になる。また、メナキノンMK−8 (H2 )を有し、ミコール酸の炭素数は44〜50、DNA中のG+C含量は69.0%であった。表に示したようにこれらの特徴はロドコッカス(Rhodococcus)属の特徴によく合致した。
従って、本菌株MCI 2956をロドコッカス エスピー(Rhodococcus sp.)と同定した。
【0017】
【表4】
Figure 0003754785
【0018】
本発明の製造方法においては、上記微生物の1種或いは2種以上が菌体及び/又は菌体調製物として用いられる。具体的には、上記微生物を培養して得られた菌体をそのまま、或いは培養して得られた菌体を公知の手法で処理して得られる調製物、即ち、アセトン処理したもの、凍結乾燥処理したもの、菌体を物理的又は酵素的に破砕したもの等の菌体調製物を用いることができる。また、これらの菌体又は菌体調製物から、上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体のカルボキシル基に作用しこれを脱炭酸及び水酸化して一般式(II)で表される3−ヒドロキシ含窒素六員環化合物へ変換する能力を有する酵素画分を粗製物或いは精製物として取り出して用いることも可能である。更には、このようにして得られた菌体、菌体調製物、酵素画分等をポリアクリルアミドゲル、カラギーナンゲル等の担体に固定化したもの等を用いることも可能である。そこで本明細書において、「菌体及び/又は該菌体調製物」の用語は、上述の菌体、菌体調製物、酵素画分、及びそれらの固定化物全てを含有する概念として用いられる。
【0019】
次に、本発明の製造方法について具体的に説明する。
本発明の製造方法において微生物は、通常、培養して用いられるが、この培養については定法通り行うことができる。本微生物の培養の為に用いられる培地には本微生物が資化しうる炭素源、窒素源、及び無機イオン等が含まれる。炭素源としては、グルコース等の炭水化物、グリセロール等のアルコール類、有機酸その他が適宜使用される。窒素源としては、NZアミン、トリプトース、酵母エキス、ポリペプトンその他が適宜使用される。無機イオンとしては、リン酸イオン、マグネシウムイオン、鉄イオン、マンガンイオン、モリブデンイオンその他が必要に応じ適宜使用される。更に、イノシトール、パルトテン酸、ニコチン酸アミドその他のビタミン類を必要に応じ添加することは有効である。培養は、好気的条件下に、pH約6〜8、温度約20〜35℃の適当な範囲に制御しつつ15〜100時間行う。
【0020】
上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体に上記微生物を作用させて3−ヒドロキシ含窒素六員環化合物を製造する方法として、本微生物を培養し、得られた菌体懸濁液に上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体を添加し反応させ3−ヒドロキシ含窒素六員環化合物を得る方法、培地に上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体を添加し培養と反応を同時に行う方法、或いは培養終了後、上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体を添加して更に反応を行う方法等を用いることができる。反応温度は15〜40℃が好ましく、pH5〜10の範囲である。上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体濃度は0.1〜10%の範囲が望ましく、必要ならば上記一般式(I)で表されるニコチン酸誘導体又は2−ピラジンカルボン酸誘導体は反応の間、追補添加される。また、必要に応じて金属イオンを添加することにより反応が促進される場合がある。
培養及び反応で得られた3−ヒドロキシ含窒素六員環化合物の採取方法としては溶媒抽出、クロマトグラフィー等、通常の分離・精製方法により行うことができる。
【0021】
【実施例】
以下に実施例を挙げて本発明を更に具体的に説明するが、その要旨を越えない限り本発明の技術分野における通常の変更をすることができる。
【実施例1】
リン酸二カリウム 3.0g/L、リン酸一カリウム 1.0g/L、2−クロロニコチン酸 4.0g/L、ソルビトール 10.0g/L、ポリペプトン4.0g/L、硫酸マグネシウム七水和物 0.5g/L、硫酸マンガン四〜五水和物 0.01g/L、イノシトール 20mg/L、ニコチン酸アミド20mg/L、チアミン塩酸塩 20mg/L、パントテン酸カルシウム 20mg/L、水(pH7.0)の組成からなる液体培地400mLに、ロドコッカス・ロドクラス(Rhodococcus rhodochrous)ATCC14350を接種し、30℃で96時間好気的に培養した。得た培養液を遠心分離し、菌体を集め50mM塩化カリウム水溶液で洗浄した。これに15g/Lのニコチン酸を含む25mMリン酸カリウム緩衝液(pH7.5)を加え、全量を400mLとし30℃で好気条件下で24時間反応させた。反応終了時の3−ヒドロキシピリジン生成蓄積量は0.85g/Lであった。
【0022】
【実施例2】
リン酸二カリウム 3.0g/L、リン酸一カリウム 1.0g/L、2−クロロニコチン酸 4.0g/L、サッカロース 10.0g/L、イーストエキス 4.0g/L、硫酸マグネシウム七水和物 0.5g/L、硫酸マンガン四〜五水和物 0.01g/L、水(pH7.0)の組成からなる液体培地100mLに、ロドコッカス・ロドクラス(Rhodococcus rhodochrous)ATCC 19150を接種し、30℃で48時間好気的に培養した。得た培養液を遠心分離し、菌体を集め50mMリン酸カリウム緩衝液(pH7.0)で洗浄した。これに15g/Lニコチン酸を含む25mMリン酸カリウム緩衝液(pH7.0)を加え、全量100mLとし30℃で好気条件下で24時間反応させた。反応終了時の3−ヒドロキシピリジン生成蓄積量は0.41g/Lであった。
【0023】
【実施例3】
使用菌株としてロドコッカス・エクイ(Rhodococcus equi)ATCC 21329を用い、実施例2に記載した培養、反応方法を実施した。24時間後、3−ヒドロキシピリジン生成蓄積量は0.22g/Lであった。
【0024】
【実施例4】
使用菌株としてロドコッカス・エスピー(Rhodococcus sp.)MCI 2956を用い、実施例2に記載した培養、反応方法を実施した。24時間後、3−ヒドロキシピリジン生成蓄積量は0.24g/Lであった。
【0025】
【実施例5】
使用菌株としてロドコッカス・エスピー(Rhodococcus sp.)IFO 13161を用い、実施例2に記載した培養方法を実施した。得た培養液を遠心分離し、菌体を集め50mMリン酸カリウム緩衝液(pH7.0)で洗浄した。これに15g/Lニコチン酸ナトリウム、及び20mM硫酸マグネシウム・七水和物を含む25mMリン酸カリウム緩衝液(pH7.0)を加え、全量100mLとし30℃で好気条件下で24時間反応させた。24時間後、3−ヒドロキシピリジン生成蓄積量は0.14g/Lであった。
【0026】
【実施例6】
リン酸二カリウム 3.0g/L、リン酸一カリウム 1.0g/L、ニコチン酸ナトリウム 6.0g/L、ソルビトール 10.0g/L、ポリペプトン4.0g/L、硫酸マグネシウム七水和物 0.5g/L、硫酸マンガン四〜五水和物 0.01g/L、水(pH7.0)の組成からなる液体培地100mLに、ロドコッカス・ロドクラス(Rhodococcus rhodochrous)ATCC 14350を接種し、30℃で90時間好気的に培養した。得た培養液を遠心分離し、菌体を集め50mMリン酸カリウム緩衝液(pH7.0)で洗浄した。これに15g/Lニコチン酸を含む25mMリン酸カリウム緩衝液(pH7.5)を加え、全量100mLとし30℃で好気条件下で24時間反応させた。反応終了時の3−ヒドロキシピリジン生成蓄積量は0.11g/Lであった。
【0027】
【発明の効果】
本発明によって、医薬の中間原料として有用である3−ヒドロキシ含窒素六員環化合物を微生物を利用して、ニコチン酸誘導体又は2−ピラジンカルボン酸誘導体から簡便に製造することが可能になった。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a method for producing a 3-hydroxy nitrogen-containing six-membered ring compound using a microorganism and / or a preparation of the microorganism. A 3-hydroxy nitrogen-containing six-membered ring compound is a substance useful as an intermediate raw material for pharmaceuticals.
[0002]
[Prior art]
Many methods for producing 3-hydroxy nitrogen-containing 6-membered ring compounds have been reported so far, but all are based on chemical synthesis methods. A method of heating 2-acetylfuran in the presence of ammonia (Journal of Medicinal Chemistry (J. Med. Chem.), 11 , 792 (1968)), a method of thermally decomposing melanoidin (Agricultural and Biological Chemistry (Agr. Biol. Chem.), 40 , 2051 (1976)), a method of photooxidizing 2-aminomethylfuran under low-temperature conditions (Chem. Pharm. Bull., 39 , 181 (1991)). Etc.
[0003]
[Problems to be solved by the invention]
The conventional chemical synthesis production method is not always satisfactory as an industrial production method in that raw materials are expensive, chlorinated organic solvents are used, and there are many impurities and problems in the recovery and purification process. Absent.
The subject of this invention is providing the method of manufacturing a 3-hydroxy nitrogen-containing 6-membered ring compound industrially cheaply.
[0004]
[Means for Solving the Problems]
As a result of intensive studies to solve the above problems, the present inventors have found a microorganism capable of producing a 3-hydroxy nitrogen-containing six-membered ring compound from nicotinic acid and completed the present invention. That is, the gist of the present invention is the general formula (I)
[Chemical 3]
Figure 0003754785
(In the formula, R 1 and R 2 each independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a carboxyl group, a cyano group, an oxime group, or an alkyl group having 1 to 5 carbon atoms, and A represents CH or A nicotinic acid derivative or a 2-pyrazinecarboxylic acid derivative represented by the following formula: a microbial cell having a hydroxylation capacity accompanying decarboxylation of the carboxyl group of the derivative and / or the microbial cell preparation. General formula (II), characterized by acting
[Formula 4]
Figure 0003754785
(Wherein R 1 , R 2 and A have the same meanings as in formula (I)).
[0005]
As a preferred embodiment of the present invention,
(1) A 3-hydroxy nitrogen-containing six-membered ring characterized by allowing microbial cells and / or a preparation of the microbial cells having hydroxylation ability accompanying decarboxylation of the carboxyl group of nicotinic acid to act on nicotinic acid Method for producing compound, and (2) causing 6-chloronicotinic acid to act on the cells of microorganisms having hydroxylation ability accompanying decarboxylation of the carboxyl group of 6-chloronicotinic acid and / or preparations of the cells A process for producing a 3-hydroxy nitrogen-containing six-membered ring compound,
I will provide a.
In addition, as said microorganisms, the microorganisms which belong to Rhodococcus genus are mentioned as a preferable thing.
Hereinafter, the method of the present invention will be described in detail.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
In the present invention, the nicotinic acid derivative or 2-pyrazinecarboxylic acid derivative represented by the above general formula (I) is used as a raw material, and the cells of the specific microorganism or the preparation of the cells is allowed to act on the derivative. A 3-hydroxy nitrogen-containing six-membered ring compound represented by the above general formula (II) is produced. In the formula, the alkyl group having 1 to 5 carbon atoms represented by R 1 and R 2 is, for example, methyl group, ethyl group, n-propyl group, iso-propyl group, n-butyl group, iso-butyl group, sec -Represents a butyl group or a tert-butyl group. Preferable examples include a case where R 1 and R 2 are a hydrogen atom or a halogen atom, and a case where A is CH . Particularly preferred examples include a case where R 1 and R 2 represent a hydrogen atom and A represents CH, and a case where R 1 represents a halogen atom, R 2 represents a hydrogen atom and A represents CH. .
[0007]
In the present invention, any microorganism can be used as long as it is a microorganism having a hydroxylation ability accompanied by decarboxylation of the carboxyl group of the nicotinic acid derivative or 2-pyrazinecarboxylic acid derivative represented by the above general formula (I). . Particularly preferred microorganisms include Rhodococcus (Rhodococcus) genus or Serratia (Serratia) microorganism belonging to the genus. Microorganism belonging to Rhodococcus (Rhodococcus) genus or Serratia (Serratia) genus for use in the present invention include, for example Rhodococcus Rodokurasu (Rhodococcus rhodochrous) ATCC 14350, Rhodococcus Rodokurasu (Rhodococcus rhodochrous) ATCC 19150, Rhodococcus equi (Rhodococcus equi) ATCC 21329, Rhodococcus sp. (Rhodococcus sp.) IFO 13161 and Rhodococcus sp. (Rhodococcus sp.) MCI 2956, Serratia Purimuchika (Serratia plymuthica) IAM 13543 and Serratia marcescens (Serratia marcescens ) IAM 12142 and the like. The above strains are all known strains except Rhodococcus sp. MCI 2956, respectively, Biotechnology Institute of Industrial Technology, Institute of Fermentation (IFO), American Type Culture Collection (ATCC) And from the Institute for Molecular Biology (IAM), the University of Tokyo. Rhodococcus sp. (Rhodococcus sp.) MCI 2956 is a bacterium that has been isolated from natural soil by the present inventors, etc., it is deposited with the Agency of life Institute of Advanced Industrial Science and Technology on January 29, 1996 as FERM P-15404 , February 6, 1997, transferred to an international deposit under the Budapest Treaty and deposited under the deposit number of FERM BP-5813. The microorganism may be a wild-type strain, a UV-irradiated mutant, an N-methyl-N′-nitro-N-nitrosoguanidine (NTG) treatment, an ethylmethanesulfonate (EMS) treatment, a nitrite treatment, an acridine treatment, or the like. Any strain such as a recombinant strain derived by a genetic technique such as cell fusion or gene recombination may be used. In the following, the mycological properties of Rhodococcus sp. MCI 2956, which is a soil isolate, are described.
[0008]
1. Morphological properties Microscopic observation was performed on a heart infusion agar medium at 30 ° C. after 9 hours and 30 hours of culture. The MCI 2956 strain becomes a mycelium in which the cells extend unevenly and branch in the early stage of culture. Thereafter, the cells become fragmented with the passage of time, resulting in a short to non-uniform shape. Divided cells do not have motility. No aerial hyphae, spores or sporangia were observed.
[0009]
2. Culture Properties ISP [International Streptomyces Project] Properties of MCI 2956 strain after culturing at 30 ° C. for 10 days on the prescribed medium are shown in Table 1 below.
[0010]
[Table 1]
Figure 0003754785
[0011]
3. Physiological properties The physiological properties of MCI 2956 strain are shown below.
(1) Growth temperature range 20-40 ° C
(2) Gelatin liquefaction Negative (3) Starch hydrolysis Negative (4) Skim milk coagulation and peptone formation Negative (5) Melanin-like pigment formation Negative (6) Use of carbon source (30 on Pridham Gotlive Agar) C. for 14 days)
Since the MCI 2956 strain showed some growth even in the control medium without the carbon source, the relative assimilation with the control as-is shown in Table 2.
[0012]
[Table 2]
Figure 0003754785
[0013]
4). Chemical taxonomic properties The chemical taxonomic properties of MCI 2956 strain are shown in Table 3.
[0014]
[Table 3]
Figure 0003754785
[0015]
5. Taxonomic considerations The strain MCI 2956 exhibits polymorphism in the cell cycle. At the initial stage of culture, the cells expand into branched mycelia, and are divided over time into short rod-like to rod-like shapes. Moreover, since it has meso-diaminopimelic acid in the cell wall and arabinose and galactose are included in the total cell sugar, it was found that the cell wall type is type IV. Furthermore, the N-acyl type of cell wall peptidoglycan was the glycolyl type. From these characteristics, it was suggested that this strain belongs to the genus Nocardiaceae or Mycobacterium. These fungal groups are known to have mycolic acid (β-hydroxy fatty acid having a long-chain alkyl group at the α-position) on the cell wall, and other chemical taxonomic features clearly define the genus. Has been done.
[0016]
Therefore, the chemical taxonomic characteristics of the Nocardiaceae and Mycobacterium genus described in this strain and Pro Procaryotes 2nd edition (1992), Volume 2, pages 1180 to 1270 were compared, and the genus level was compared. Was identified. Table 4 compares the morphology and chemical taxonomic characteristics of this strain and the mycobacteria belonging to the Nocardiaceae family. This strain becomes a mycelium in which cells are elongated and branched in the early stage of culture. Also has menaquinone MK-8 (H 2), carbon atoms of mycolic acids 44-50, G + C content in DNA was 69.0%. As shown in the table, these characteristics matched well with those of the genus Rhodococcus .
Therefore, this strain MCI 2956 was identified as Rhodococcus sp.
[0017]
[Table 4]
Figure 0003754785
[0018]
In the production method of the present invention, one or more of the above microorganisms are used as the microbial cells and / or the microbial cell preparation. Specifically, the cells obtained by culturing the above microorganisms as they are or the preparations obtained by treating the cells obtained by culturing by known methods, that is, those treated with acetone, lyophilized Cell preparations such as those that have been treated and those that have been physically or enzymatically disrupted can be used. In addition, from these cells or cell preparations, it acts on the carboxyl group of the nicotinic acid derivative or 2-pyrazinecarboxylic acid derivative represented by the above general formula (I) to decarboxylate and hydroxylate the general formula. The enzyme fraction having the ability to convert to a 3-hydroxy nitrogen-containing six-membered ring compound represented by (II) can be taken out and used as a crude product or a purified product. Furthermore, it is also possible to use a product obtained by immobilizing a bacterial cell, a bacterial cell preparation, an enzyme fraction and the like thus obtained on a carrier such as polyacrylamide gel and carrageenan gel. Therefore, in the present specification, the term “bacteria body and / or cell body preparation” is used as a concept including all of the above-mentioned cell bodies, cell body preparations, enzyme fractions, and their immobilized products.
[0019]
Next, the production method of the present invention will be specifically described.
In the production method of the present invention, the microorganism is usually used after being cultured, but this culture can be carried out as usual. The medium used for culturing the microorganism includes a carbon source, a nitrogen source, inorganic ions, and the like that can be assimilated by the microorganism. As the carbon source, carbohydrates such as glucose, alcohols such as glycerol, organic acids and the like are appropriately used. As the nitrogen source, NZ amine, tryptose, yeast extract, polypeptone and the like are appropriately used. As the inorganic ions, phosphate ions, magnesium ions, iron ions, manganese ions, molybdenum ions and others are appropriately used as necessary. Furthermore, it is effective to add inositol, partothenic acid, nicotinamide or other vitamins as necessary. Cultivation is carried out under aerobic conditions for 15 to 100 hours while controlling the pH within a suitable range of about 6 to 8 and temperature of about 20 to 35 ° C.
[0020]
As a method for producing a 3-hydroxy nitrogen-containing six-membered ring compound by reacting the above microorganism with the nicotinic acid derivative or 2-pyrazinecarboxylic acid derivative represented by the above general formula (I), the microorganism is cultured and obtained. A method for obtaining a 3-hydroxy nitrogen-containing six-membered ring compound by adding a nicotinic acid derivative or 2-pyrazinecarboxylic acid derivative represented by the above general formula (I) to the cell suspension and reacting the suspension, and a medium containing the above general formula A method in which a nicotinic acid derivative or 2-pyrazinecarboxylic acid derivative represented by (I) is added and culture and reaction are carried out simultaneously, or after completion of culturing, a nicotinic acid derivative or 2-pyrazine represented by the above general formula (I) For example, a method in which a carboxylic acid derivative is added and further reacted can be used. The reaction temperature is preferably 15 to 40 ° C., and is in the range of pH 5 to 10. The concentration of the nicotinic acid derivative or 2-pyrazinecarboxylic acid derivative represented by the general formula (I) is preferably in the range of 0.1 to 10%, and if necessary, the nicotinic acid derivative represented by the general formula (I) or The 2-pyrazinecarboxylic acid derivative is supplemented during the reaction. Moreover, reaction may be accelerated | stimulated by adding a metal ion as needed.
As a method for collecting the 3-hydroxy nitrogen-containing six-membered ring compound obtained by the culture and reaction, it can be carried out by usual separation / purification methods such as solvent extraction and chromatography.
[0021]
【Example】
The present invention will be described more specifically with reference to the following examples. However, ordinary changes in the technical field of the present invention can be made without departing from the gist thereof.
[Example 1]
Dipotassium phosphate 3.0 g / L, monopotassium phosphate 1.0 g / L, 2-chloronicotinic acid 4.0 g / L, sorbitol 10.0 g / L, polypeptone 4.0 g / L, magnesium sulfate heptahydrate 0.5 g / L, manganese sulfate tetra-pentahydrate 0.01 g / L, inositol 20 mg / L, nicotinamide 20 mg / L, thiamine hydrochloride 20 mg / L, calcium pantothenate 20 mg / L, water (pH 7) 0.0) was inoculated with Rhodococcus rhodochrous ATCC 14350 and cultured aerobically at 30 ° C. for 96 hours. The obtained culture broth was centrifuged, and the cells were collected and washed with 50 mM aqueous potassium chloride solution. A 25 mM potassium phosphate buffer solution (pH 7.5) containing 15 g / L of nicotinic acid was added thereto to make a total volume of 400 mL, and reacted at 30 ° C. under aerobic conditions for 24 hours. The amount of 3-hydroxypyridine produced and accumulated at the end of the reaction was 0.85 g / L.
[0022]
[Example 2]
Dipotassium phosphate 3.0 g / L, monopotassium phosphate 1.0 g / L, 2-chloronicotinic acid 4.0 g / L, saccharose 10.0 g / L, yeast extract 4.0 g / L, magnesium sulfate hemihydrate Inoculate Rhodococcus rhodochrous ATCC 19150 into 100 mL of a liquid medium consisting of a composition of Japanese 0.5 g / L, manganese sulfate tetra-pentahydrate 0.01 g / L, water (pH 7.0), Cultured aerobically at 30 ° C. for 48 hours. The obtained culture broth was centrifuged, and the cells were collected and washed with 50 mM potassium phosphate buffer (pH 7.0). A 25 mM potassium phosphate buffer solution (pH 7.0) containing 15 g / L nicotinic acid was added thereto to make a total volume of 100 mL, and reacted at 30 ° C. under aerobic conditions for 24 hours. The amount of 3-hydroxypyridine produced and accumulated at the end of the reaction was 0.41 g / L.
[0023]
[Example 3]
The culture and reaction method described in Example 2 was carried out using Rhodococcus equi ATCC 21329 as the strain used. After 24 hours, the amount of 3-hydroxypyridine produced and accumulated was 0.22 g / L.
[0024]
[Example 4]
The culture and reaction method described in Example 2 was carried out using Rhodococcus sp. MCI 2956 as the strain used. After 24 hours, the amount of 3-hydroxypyridine produced and accumulated was 0.24 g / L.
[0025]
[Example 5]
The culture method described in Example 2 was carried out using Rhodococcus sp. IFO 13161 as the strain used. The obtained culture broth was centrifuged, and the cells were collected and washed with 50 mM potassium phosphate buffer (pH 7.0). To this, 25 g potassium phosphate buffer (pH 7.0) containing 15 g / L sodium nicotinate and 20 mM magnesium sulfate heptahydrate was added to make a total volume of 100 mL and allowed to react at 30 ° C. under aerobic conditions for 24 hours. . After 24 hours, the amount of 3-hydroxypyridine produced and accumulated was 0.14 g / L.
[0026]
[Example 6]
Dipotassium phosphate 3.0 g / L, Monopotassium phosphate 1.0 g / L, Sodium nicotinate 6.0 g / L, Sorbitol 10.0 g / L, Polypeptone 4.0 g / L, Magnesium sulfate heptahydrate 0 Inoculate Rhodococcus rhodochrous ATCC 14350 into 100 mL of a liquid medium consisting of 0.5 g / L, manganese sulfate tetra-pentahydrate 0.01 g / L, water (pH 7.0). Cultured aerobically for 90 hours. The obtained culture broth was centrifuged, and the cells were collected and washed with 50 mM potassium phosphate buffer (pH 7.0). A 25 mM potassium phosphate buffer solution (pH 7.5) containing 15 g / L nicotinic acid was added thereto to make a total volume of 100 mL, and reacted at 30 ° C. under aerobic conditions for 24 hours. The amount of 3-hydroxypyridine produced and accumulated at the end of the reaction was 0.11 g / L.
[0027]
【The invention's effect】
According to the present invention, it has become possible to easily produce a 3-hydroxy nitrogen-containing six-membered ring compound, which is useful as an intermediate raw material for pharmaceuticals, from a nicotinic acid derivative or a 2-pyrazinecarboxylic acid derivative using a microorganism.

Claims (1)

一般式(I)
Figure 0003754785
(式中、R1 及びR2 は水素原子を表し、AはCHを表す。)で表されるニコチン酸に、ロドコッカス・ロドクラス(Rhodococcus rhodochrous)ATCC 14350、ロドコッカス・ロドクラス(Rhodococcus rhodochrous)ATCC 19150、ロドコッカス・エクイ(Rhodococcus equi)ATCC 21329、ロドコッカス・エスピー(Rhodococcus sp.)IFO 13161及びロドコッカス・エスピー(Rhodococcus sp.)MCI 2956(FERM BP−5813)の群から選ばれる菌株の菌体及び/又は該菌体調製物を作用させることを特徴とする、一般式(II)
Figure 0003754785
(式中、R1 、R2 及びAは式(I)と同義である。)で表される3−ヒドロキシ含窒素六員環化合物の製造方法。
Formula (I)
Figure 0003754785
(Wherein R 1 and R 2 represent a hydrogen atom, and A represents CH ), nicotinic acid represented by Rhodococcus rhodochrous ATCC 14350, Rhodococcus rhodochrous ATCC 19150, A strain of Rhodococcus equi ATCC 21329, Rhodococcus sp. IFO 13161 and Rhodococcus sp. MCI 2956 (FERM BP-5813) or a strain thereof A general formula (II) characterized by acting a cell preparation
Figure 0003754785
(In formula, R < 1 >, R < 2 > and A are synonymous with Formula (I).) The manufacturing method of the 3-hydroxy nitrogen-containing 6-membered ring compound represented.
JP2916097A 1996-02-15 1997-02-13 Method for producing 3-hydroxy nitrogen-containing six-membered ring compound Expired - Fee Related JP3754785B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2916097A JP3754785B2 (en) 1996-02-15 1997-02-13 Method for producing 3-hydroxy nitrogen-containing six-membered ring compound

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2784496 1996-02-15
JP8-27844 1996-02-15
JP2916097A JP3754785B2 (en) 1996-02-15 1997-02-13 Method for producing 3-hydroxy nitrogen-containing six-membered ring compound

Publications (2)

Publication Number Publication Date
JPH09275992A JPH09275992A (en) 1997-10-28
JP3754785B2 true JP3754785B2 (en) 2006-03-15

Family

ID=26365828

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2916097A Expired - Fee Related JP3754785B2 (en) 1996-02-15 1997-02-13 Method for producing 3-hydroxy nitrogen-containing six-membered ring compound

Country Status (1)

Country Link
JP (1) JP3754785B2 (en)

Also Published As

Publication number Publication date
JPH09275992A (en) 1997-10-28

Similar Documents

Publication Publication Date Title
US4624920A (en) Process for the preparation of dicarboxylic acid using microorganism
JPH0499497A (en) Production of optically active lactic acid
US4774179A (en) Process for preparing a 7-aminocephalosporanic acid compound
JPH04365494A (en) Microbiological method for producing hydroxylated pyrazine derivative
JP3014171B2 (en) Method for producing 4-halo-3-hydroxybutyramide
JP4857114B2 (en) Method for producing 2-hydroxy-4-substituted pyridine
JP3754785B2 (en) Method for producing 3-hydroxy nitrogen-containing six-membered ring compound
JPH06141888A (en) Production of d-mandelic acid
JP3957053B2 (en) Novel microorganism and method for producing pravastatin
EP0790315B1 (en) Method for producing 3-hydroxy nitrogen-containing six-membered cyclic compound
JPS63157986A (en) Production of l-phenylalanine by gene recombination
JP3873512B2 (en) Method for producing D-3- (2-naphthyl) alanine
JPH04304893A (en) Production of hydroxide of nitrogen-containing heterocyclic compound by microorganism
JPH09234092A (en) Production of nitrile compound
JP3743172B2 (en) Method for producing L-homocysteine
JP3090761B2 (en) Production method of optically active lactic acid
JPH1014591A (en) Production of 2-hydroxy-nitrogen-containing 6-membered ring compound
JPH0378106B2 (en)
JPH0728750B2 (en) Method for producing hydroxide of pyrazinic acid by microorganism
JP5126707B2 (en) Method for producing α-hydroxyacylpyridine
JPH10262691A (en) Production of 3-hydroxy nitrogen-containing 6-membered ring compound
JPH11192097A (en) Production of optically active alpha-mercaptocarboxylic acid
JP2702764B2 (en) Method for producing (7S) -cyclopenta [d] pyrimidine derivative
JPWO2002077203A1 (en) Selection medium for beauveriolide I substance or beauveriolide III substance and method for selective production thereof
JPH09234093A (en) Production of organic acid

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050329

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050526

A521 Written amendment

Effective date: 20050526

Free format text: JAPANESE INTERMEDIATE CODE: A821

A131 Notification of reasons for refusal

Effective date: 20050802

Free format text: JAPANESE INTERMEDIATE CODE: A131

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051101

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20051213

A61 First payment of annual fees (during grant procedure)

Effective date: 20051219

Free format text: JAPANESE INTERMEDIATE CODE: A61

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 4

Free format text: PAYMENT UNTIL: 20091222

LAPS Cancellation because of no payment of annual fees